PainChek Accelerates US Expansion with Sabra Deal and 7% ARR Growth

Sabra Deal Validates US Growth Strategy

PainChek (ASX:PCK) has landed a significant master service agreement with Nasdaq-listed Sabra Health Care REIT, gaining access to 350 aged care homes in the US and an annual recurring revenue (ARR) opportunity of A$2 million. This deal, inked after the quarter ended 31 March 2026, marks a key milestone in PainChek’s push into the North American market, complementing its existing partnerships with PointClickCare and Mayo Clinic. Sabra’s commitment to roll out PainChek across 20,000 beds underlines the growing appetite for AI-driven pain assessment in US aged care facilities, a sector with a vast 2.9 million bed market opportunity. This contract builds on PainChek's FDA clearance and recent pipeline momentum from US healthcare conferences, positioning the company to scale rapidly in the region. The initial homes are already being contracted, with a waiting list forming for subsequent deployments, highlighting strong demand. This development follows the company's earlier major $5B Sabra REIT deal announcement in April.

Global Licence Growth Fuels Revenue Expansion

PainChek’s global footprint continues to expand with contracted licences climbing 7% quarter-on-quarter to 118,577 across more than 2,000 aged care facilities worldwide, underpinning a $5.9 million ARR once fully implemented. Implemented licences rose 16% to 85,200, generating $4.2 million ARR, driven primarily by growth in Australia/New Zealand and the UK. The UK market alone added 4,000 new licences in the quarter, a 12% increase, reflecting strong uptake supported by robust clinical outcome data and return on investment (ROI) modelling. This growth trajectory is consistent with the company’s strategy of leveraging clinical validation and integration partnerships to drive adoption, as seen in the recent 4,000 new UK licences growth report. Global retention rates remain steady at around 85%, supported by increasing utilisation; cumulative PainChek assessments nearly doubled to 18.8 million over the past year, a testament to the platform’s growing clinical utility.

Product Innovation and Market Diversification

Alongside its core aged care business, PainChek is refining its Infant app with a May 2026 update introducing educational tools and subscription pricing enhancements aimed at expanding parental education and healthcare professional channels in Australia, with plans for international rollout in early 2027. Partnerships with pharmacy-led distributors and social media ambassadors are designed to boost awareness and uptake in this nascent market segment. This diversification complements ongoing research collaborations with institutions like the University of Oxford and University of Granada, underpinning PainChek’s evidence-based approach to pain assessment across age groups and geographies.

Financial Position and Funding Outlook

Financially, PainChek reported recognised customer revenue of $2.68 million for the nine months to March 2026, up 5.4% year-on-year, reflecting steady commercialisation progress. Cash reserves stood at $2.3 million at quarter-end, down from $4.8 million the prior quarter, with operating cash outflows of $2.48 million reflecting ongoing investments in sales, marketing, and R&D. The company expects a $1.1 million R&D tax refund in Q2 2026, which will bolster liquidity. PainChek is actively negotiating additional funding, including a loan secured against the R&D incentive, to extend its cash runway beyond the current estimated 0.9 quarters. The company’s ability to sustain operations hinges on continued customer renewals, new sales, and investor support, as outlined in its latest cashflow guidance. This financial backdrop aligns with the challenges and opportunities described in the earlier FDA clearance and funding update from February 2026.